Model for Microcapsule Drug Release with Ultrasound-Activated Enhancement

Area of Science:

• Materials Science
• Biomedical Engineering
• Nanotechnology

Background:

• Drug delivery vehicles are crucial for targeted therapy.
• Microbubbles and microcapsules offer potential for controlled substance release.
• Silane-polycaprolactone (SiPCL) and silica/mercaptosilica (S/M/S) are investigated as potential drug carriers.

Purpose of the Study:

• To compare the drug loading and release characteristics of SiPCL and S/M/S microcapsules.
• To evaluate the effect of ultrasound on drug release kinetics.
• To assess the efficacy of ultrasound-triggered drug release in cancer cell models.

Main Methods:

• Encapsulation of lucigenin (fluorescent dye) into SiPCL and S/M/S microcapsules.
• Characterization of drug loading capacity and release profiles using Langmuir isotherm and Weibull function.
• Investigation of ultrasound-induced drug release.
• Assessment of docetaxel's effect on C4-2B prostate cancer cells.

Main Results:

• SiPCL microcapsules exhibited significantly higher lucigenin loading capacity compared to S/M/S microcapsules.
• SiPCL demonstrated a slower, tunable drug release profile, with dissolution times up to 10 days.
• Ultrasound (insonation) reduced the dissolution time of SiPCL microcapsules to 2 days.
• Ultrasound-enhanced docetaxel release from SiPCL improved C4-2B prostate cancer cell toxicity.

Conclusions:

• SiPCL microcapsules are superior drug delivery vehicles due to higher loading and controlled release.
• Ultrasound provides a mechanism for triggered, localized drug release.
• This approach enhances therapeutic efficacy, particularly for localized cancer treatment.